Key Findings
Japan has authorized the first two commercial cell therapies based on induced pluripotent stem cells (iPSC). One of these treatments targets Parkinson’s Disease, utilizing allogeneic iPSC-derived dopaminergic neural progenitor cells to restore dopamine generation in the brain.
Technical Details
The therapy involves injections into the putamen/striatum. Key technical observations from the clinical trial include:
- Cell Type: The treatment uses progenitor cells rather than the final derived product.
- Cell Source: The therapy is allogeneic rather than personalized.
- Clinical Results: A 2-year trial reported improvements in motor skills.
- Safety: This is the first iPSC clinical trial confirming that iPS-cell-derived progenitors can produce neurons in the putamen of Parkinson’s patients without forming tumours.
Background & Context
The development of this therapy builds upon iPSC technology, which was first developed in Japan and awarded the Nobel Prize in 2012 by Shinya Yamanaka. The current commercial application is priced at ¥55,306,737. The source references research by Nobukatsu Sawamoto, Daisuke Doi, and Etsuro Nakanishi published in Nature (2025).
Significance & Outlook
While the therapy is now authorized, it remains under a conditional window. Sumitomo Pharma is required to conduct mandatory Phase IV post-marketing surveillance over a 7-year window. This period will be used to collect additional safety and efficacy data before full, permanent approval can be considered.
Source: https://projectcredo.com/posts/659
Get our weekly technology intelligence — free
Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.
Subscribe Free — Weekly Tech Intelligence
By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.
- Your email and selected fields are used only to deliver the newsletter.
- We never share your information with third parties.
- You can unsubscribe anytime via the link in each email.
See our Privacy Policy for details.
Takes about a minute · Unsubscribe anytime
